Biotech

Live from ASH 2022 | Ascentage Pharma Presents Latest Data of APG-2575, Including Encouraging Results of the Combination with BTKi in Patients with R/R CLL/SLL

2022-12-13 17:39 1648

SUZHOU, China and ROCKVILLE, Md. , Dec. 13, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that it has released preliminary results from a ...

Firmenich recognized for global environmental leadership with fifth CDP triple "A"

2022-12-13 15:00 1750

One of only two companies worldwide to achieve top ratings in climate, water and forests for five consecutive years GENEVA, Dec. 13, 2022 /PRNewswire/ -- Firmenich, the world's largest privately-owned fragrance and taste company, has been awarded a fifth consecutive triple "A" by CDP for the Gro...

RemeGen's RC118 for Injection Targeting Claudin 18.2 in Patients with Gastric and Pancreatic Cancers Granted Two Orphan Drug Designations by U.S. FDA

2022-12-13 12:30 2019

YANTAI, China, Dec. 13, 2022 /PRNewswire/ -- RemeGen Co., Ltd.  ("RemeGen" or "the Company") (9995.HK, SHA: 688331), a commercial-stage biotechnology company, announced onDecember 7, 2022, that its latest antibody-drug conjugate (ADC), RC118 for injection, has been grante...

CSL Announces Next CEO & Managing Director

2022-12-13 07:23 3192

Dr Paul McKenzie appointed Chief Executive Officer and Managing Director of CSL from6 March 2023 MELBOURNE, Australia, Dec. 13, 2022 /PRNewswire/ -- The Board of Directors of CSL Limited (ASX:CSL; USOTC:CSLLY) today announces that it has appointed DrPaul McKenzie as Chief Executive Officer (CEO)...

Ascletis Announces Positive Phase I Clinical Results of Oral RdRp Inhibitor ASC10 for COVID-19

2022-12-12 23:29 3640

--The exposure of active drug ASC10-A after twice daily dosing 800 mg double prodrug ASC10 in Chinese subjects was 94% of that after twice daily dosing 800 mg single prodrug molnupiravir in Japanese subjects --Based on Ascletis' Phase I results of ASC10 and molnupiravir's clinical efficacy data ...

PharmAbcine Announces Collaboration Agreement with MSD to Evaluate Anti-VISTA Antibody PMC-309 in Combination with KEYTRUDA® (pembrolizumab)

2022-12-12 21:00 1682

DAEJEON, South Korea, Dec. 12, 2022 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next-generation antibody therapeutics, announced today that the Company has entered into a clinical collaboration agreement with MSD (Merck & Co...

JW Therapeutics Presents Latest Clinical Data on Carteyva® in Follicular Lymphoma and Mantle Cell Lymphoma at the 64th ASH Annual Meeting

2022-12-12 18:00 4163

SHANGHAI, Dec. 12, 2022 /PRNewswire/ -- JW Therapeutics (HKEX: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products, presented the latest clinical data on Carteyva® (relmacabtagene autoleucel injection) in...

Avalon SteriTech Raises US$9M in Pre-Series A Funding to Accelerate its Overseas Expansion and Product Development

2022-12-12 10:00 2149

The funding round joined by SoftBank Robotics Group and Cyberport Macro Fund HONG KONG, Dec. 12, 2022 /PRNewswire/ --  Avalon SteriTech ("Avalon"), a global start-up specializing in public health and environmental hygiene solutions, announced the close of a US$9 million funding in Pre-Series A rou...

Gracell Biotechnologies Presents Clinical Data for FasTCAR-T GC012F for High Risk, Newly Diagnosed Multiple Myeloma Demonstrating 100% Overall Response Rate

2022-12-11 07:15 3543

BCMA/CD19 dual-targeting FasTCAR-T GC012F data from ongoing clinical trial presented at 64th American Society of Hematology Annual Meeting and Exposition SAN DIEGO and SUZHOU and SHANGHAI, China, Dec. 10, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL)...

Goodwin Biotechnology Inc. is now GBI, as Part of their Rebranding Initiative on their 30-Year Anniversary!

2022-12-10 04:16 2987

PLANTATION, Fla., Dec. 10, 2022 /PRNewswire/ -- Goodwin Biotechnology, Inc. announces its new name, GBI, as part of a rebranding initiative to commemorate its 30-year anniversary. This includes a new name, logo and website to reflect its evolution from an early-stage clinical manufacturing Contra...

Treadwell Therapeutics Announces A Presentation at the 2022 SABCS Annual Meeting Featuring a Clinical Trial Update on CFI-402257, a Best-in-Class TTK inhibitor

2022-12-09 22:30 6388

NEW YORK, Dec. 9, 2022 /PRNewswire/ -- Treadwell Therapeutics, a clinical-stage biotechnology company developing novel medicines for highly aggressive cancers, today announced that data presented on the ongoing CFI-402257-CL-001 clinical study of the Company's CFI-402257 program in advanced solid...

Shenzhen Holds 2022 Global Investment Promotion Conference to Build a Magnet for International Investors

2022-12-09 11:16 1576

SHENZHEN, China, Dec. 8, 2022 /PRNewswire/ -- Shenzhen welcomes outstanding investors from all over the world. The 2022 Shenzhen Global Investment Promotion Conference will be held inShenzhen, China on December 9. A number of major projects in the fields of information technology, artificial int...

ReviR Therapeutics to Present at RNA Targeted Drug Discovery Summit

2022-12-08 23:00 2326

SAN FRANCISCO, Calif., Dec. 8, 2022 /PRNewswire/ -- ReviR Therapeutics (ReviR), a biotechnology company developing small molecule therapies targeting RNA, today announced an upcoming presentation at the 5th Annual RNA Targeted Drug Discovery conference taking placeDecember 13-15, 2022 in Boston, ...

TrialWire Awarded by Frost & Sullivan for Innovative Clinical Trial Patient Recruitment Technology Platform

2022-12-08 22:00 2969

TrialWire delivers superior trial patient recruitment solutions based on highly sophisticated information technology (IT) all in one secure platform SAN ANTONIO, Dec. 8, 2022 /PRNewswire/ -- Based on its recent analysis of the clinical trial patient recruitment IT solutions industry,Frost & Sulli...

CABIO Showcases the Latest Research Results and Innovative Solutions at Food Ingredients Europe 2022

2022-12-08 21:00 1827

PARIS, Dec. 8, 2022 /PRNewswire/ -- On December 6, 2022, CABIO Biotech (Wuhan) Co., Ltd (CABIO), a leading Chinese biotechnology company, took part in the three-day Food Ingredients Europe 2022 (Fi Europe) held inParis, France. Fi Europe has been recognized as the industry's highest level interna...

PharmAbcine to Participate in the 41th Annual J.P. Morgan Healthcare Conference and Biotech Showcase™ 2023 during JPM Week

2022-12-08 21:00 1538

DAEJEON, South Korea, Dec. 8, 2022 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next-generation antibody therapeutics, announced today that the Company is invited to participate in upcoming 41th Annual J.P. Morgan Healthcare ...

Ascletis Announces IND Approval of Oral 3CLpro Inhibitor ASC11 for COVID-19 by China NMPA

2022-12-07 18:10 2708

--The objective of Phase I clinical trial is to identify a safe and efficacious dose for the pivotal Phase II/III in COVID-19 patients. Phase I clinical trial is expected to be completed within the first quarter of 2023 --Phase I clinical trial will also determine if ASC11 needs to be boosted by ...

Veeva Pulse Shows Digitally Enabled Field Teams are Using HCP Time More Effectively in Asia Pacific

2022-12-07 08:00 2346

HCP Access is selective as nearly half meet with only one company monthly SINGAPORE, Dec. 7, 2022 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced findings from the latestVeeva Pulse Field Trends Report , the largest glob...

Turn Biotechnologies Changes Paradigm in Skin Rejuvenation

2022-12-06 22:00 2554

* Data unveiled at four industry conferences suggest a single ERA treatment may be more effective than combination therapies used today * Biomarker analysis demonstrates ERA's regenerative impact on fibroblast proliferation, collagen VII production * eTurna™ lipid-based delivery platform p...

Newtown's Apple to Highly Saturated Global Molecular Market, TIANGEN TGuide S16 Automated Nucleic Acid Extractor Showcased at Cell Bio 2022

2022-12-06 21:04 1680

WASHINGTON, Dec. 6, 2022 /PRNewswire/ -- TIANGEN, a high-tech biological enterprise, demonstrated its revolutionary nucleic acid extraction solution at Cell Bio 2022, the joint meeting of the American Society for Cell Biology (ASCB) and European Molecular Biology Organization (EMBO), fromDec 4 to...

1 ... 61626364656667 ... 150